Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Top Cited Papers
Open Access
- 1 January 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (1) , 14-24
- https://doi.org/10.1158/1078-0432.ccr-07-1033
Abstract
As breast cancer survival is increased by the diagnosis of earlier-stage disease and treatments improve, the side effects of cancer treatments, such as cardiotoxicity, remain clinically important. Although physicians have known for 30 years that anthracyclines cause acute and chronic cardiotoxicity, the cardiotoxic effects of radiation therapy, hormonal therapy (including tamoxifen and the aromatase inhibitors), and chemotherapy with taxanes and trastuzumab treatment have emerged more recently. This review examines the cardiac toxicity of adjuvant therapy, monitoring for early changes and existing guidelines for monitoring cardiac function in patients with breast cancer.Keywords
This publication has 117 references indexed in Scilit:
- Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same RegimenClinical Cancer Research, 2007
- Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart FailureThe Journal of Heart and Lung Transplantation, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the AdultJournal of the American College of Cardiology, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJournal of the American College of Cardiology, 2000
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987